ALVR107 / Kalaris Therapeutics - LARVOL DELTA

AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook (BioSpace) - "Preclinical and IND-enabling studies of ALVR107 to treat and cure hepatitis B will be completed in 2022 to support advancement into a POC study."

Preclinical • Hepatitis B • Infectious Disease

AlloVir Reports Third Quarter 2021 Financial Results (Streetinsider.com) - "Preclinical and Investigational New Drug (IND)-enabling studies for ALVR107 to treat hepatitis B virus (HBV) are on track for completion by the end of this year. Chronic HBV infection is associated with significant morbidity and mortality. Current treatment options for chronic HBV consist of life-long antiviral therapy to suppress virus replication, which can slow the progression of liver cirrhosis and reduce the incidence of liver cancer. However, there are no curative therapies available."

Preclinical • Hepatitis B • Infectious Disease

AlloVir Reports First Quarter 2021 Financial Results (Businesswire) - "The company is on track to complete preclinical and IND-enabling studies for both ALVR107 to treat hepatitis B virus...in the second half of 2021...Research and development expenses were $20.4 million for the quarter ended March 31, 2021, compared to $6.8 million for the quarter ended March 31, 2020."

Commercial • Preclinical • Hepatitis B • Infectious Disease